Genovis AB
GENO
Rank in Stocks
#18181
Genovis AB (publ.) develops and sells tools for the development of new... Genovis AB (publ.) develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia. The company provides FabRICATOR, FabALACTICA, FabRICATOR Z, GingisKHAN, FabULOUS (SpeB), a cysteine protease; FabDELLO, a protease that digests human IgG1; IgASAP, an IgA-digesting enzyme; and IgMBRAZOR, an IgM-specific protease. It also offers GlySERIAS, an enzyme that digests flexible glycine-rich fusion protein linkers; GlyCLICK, a conjugation technology; TransGLYCIT, a platform technology; and GingisREX, a protease that digests proteins C-terminally of arginine residues. In addition, the company offers OmniGLYZOR, a mixture of immobilized enzymes; PNGase F, a glycoamidase; OpeRATOR, an O-glycan-specific protease; ImpaRATOR, an O-glycan-dependent protease; OglyZOR, an endoglycosidase; SialEXO, a sialidase product; FucosEXO, a mix of a-Fucosidases; GalactEXO, a ß-Galactosidase mix; GalNAcEXO, an a-N-Acetylgalactosaminidase; and GlycOCATCH, an affinity resin. Further, it provides GlycINATOR (EndoS2), an IgG-specific endoglycosidase; IgGZERO (EndoS), an IgG-specific endoglycosidase; Anti-FabRICATOR (Anti-IdeS), a family of antibody products; and Anti-FabRICATOR Z (Anti-IdeZ), a goat polyclonal antibody, as well as SEQURNA RNase Inhibitor Thermostable. Additionally, the company offers antibodies, proteins, antigens, kits, and cell culture products; bioprocess and gene therapy services; and services, such as SmartEnzymes fragmentation and conjugation, antibody LC-MS analysis, and customized antibody services. It serves biotech and pharmaceutical, contract research, and contract manufacturing companies. The company was founded in 1999 and is headquartered in Kävlinge, Sweden.
Share Price
$2.14
Last synced: 2026-11-09
Market Cap
$141.54M
Change (1 day)
0.44%
Change (1 year)
-4.27%
Country
Stock data: Financial Modeling Prep·Updated ·Not investment advice·How we calculate this
Trade Genovis AB (GENO)
Category
Healthcare
EPS for Genovis AB (GENO)
EPS as of June 2026 TTM: $0.03
According to Genovis AB's latest financial reports, its current EPS (TTM) is $0.03. At the end of 2025 the company had an EPS of $0.04, a decrease compared to its 2024 EPS of $0.05.
EPS history for Genovis AB from 2008 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $0.03 | -24.25% |
| 2025 | $0.04 | -13.91% |
| 2024 | $0.05 | -51.39% |
| 2023 | $0.09 | 471.78% |
| 2022 | $0.02 | -61.19% |
| 2021 | $0.04 | 250.00% |
| 2020 | $0.01 | -25.47% |
| 2019 | $0.02 | -619.35% |
| 2018 | 0.00 | -81.87% |
| 2017 | $-0.02 | -51.42% |
| 2016 | $-0.04 | -55.04% |
| 2015 | $-0.08 | -37.01% |
| 2014 | $-0.12 | 5.34% |
| 2013 | $-0.12 | -42.27% |
| 2012 | $-0.20 | -8.59% |
| 2011 | $-0.22 | -30.21% |
| 2010 | $-0.32 | -69.95% |
| 2009 | $-1.07 | -51.63% |
| 2008 | $-2.20 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | 51,583.17% |
US
|
|
| $-7.07 | -23,433.33% |
US
|
|
| $-5.29 | -17,558.75% |
AU
|
|
| $12.88 | 42,408.58% |
BE
|
|
| $21.56 | 71,055.12% |
NL
|
Questions about Genovis AB's earnings per share (EPS)
What is Genovis AB's earnings per share (EPS)?
Genovis AB's earnings per share (EPS) over the last twelve months is $0.03, as of Jun 2026.
What was Genovis AB's earnings per share (EPS) in 2025?
In 2025, Genovis AB's earnings per share (EPS) was $0.04, 20.00% less than in 2024 ($0.05).
How has Genovis AB's earnings per share (EPS) changed since 2020?
From 2020 to 2025, Genovis AB's earnings per share (EPS) went from $0.01 to $0.04, an average growth of 31.95% a year.
How does Genovis AB's earnings per share (EPS) compare with similar companies?
Genovis AB's earnings per share (EPS) ($0.03) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.